141,402 Shares in Elanco Animal Health Incorporated $ELAN Purchased by Intech Investment Management LLC

Intech Investment Management LLC acquired a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 141,402 shares of the company’s stock, valued at approximately $3,166,000.

Several other large investors have also made changes to their positions in the business. Anchor Investment Management LLC acquired a new stake in shares of Elanco Animal Health in the second quarter worth $29,000. Covestor Ltd raised its holdings in shares of Elanco Animal Health by 48.2% during the third quarter. Covestor Ltd now owns 1,383 shares of the company’s stock worth $31,000 after purchasing an additional 450 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new position in Elanco Animal Health during the second quarter valued at $35,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Elanco Animal Health during the second quarter valued at $38,000. Finally, Fulcrum Asset Management LLP acquired a new position in Elanco Animal Health during the third quarter valued at $36,000. 97.48% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Elanco Animal Health news, insider Timothy Bettington sold 4,350 shares of Elanco Animal Health stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $23.00, for a total value of $100,050.00. Following the completion of the transaction, the insider owned 138,911 shares of the company’s stock, valued at approximately $3,194,953. The trade was a 3.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.14% of the company’s stock.

Elanco Animal Health Price Performance

NYSE:ELAN opened at $26.32 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.09 and a quick ratio of 1.07. The firm has a market cap of $13.15 billion, a price-to-earnings ratio of -87.72, a price-to-earnings-growth ratio of 2.26 and a beta of 1.73. The company has a 50 day moving average price of $23.59 and a 200-day moving average price of $23.92. Elanco Animal Health Incorporated has a 1-year low of $19.40 and a 1-year high of $27.98.

Elanco Animal Health (NYSE:ELAN – Get Free Report) last posted its earnings results on Friday, November 6th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.07. Elanco Animal Health had a negative net margin of 2.86% and a positive return on equity of 8.80%. The firm had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.21 billion. During the same period in the previous year, the business posted $0.19 EPS. The business’s revenue was up 11.3% compared to the same quarter last year. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. Equities research analysts forecast that Elanco Animal Health Incorporated will post 1.18 EPS for the current year.

Elanco Animal Health announced that its board has approved a share buyback plan on Thursday, November 19th that allows the company to buy back $600 million in shares. This buyback authorization allows the company to repurchase up to 4.5% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s management believes its stock is undervalued.

Analyst Ratings Changes

ELAN has been the topic of several recent research reports. KeyCorp reaffirmed an “overweight” rating on shares of Elanco Animal Health in a report on Monday, November 9th. Morgan Stanley reduced their price objective on Elanco Animal Health from $26.00 to $25.00 and set an “equal weight” rating for the company in a research note on Thursday, October 29th. The Goldman Sachs Group initiated coverage on Elanco Animal Health in a report on Friday, October 16th. They issued a “buy” rating and a $32.00 price objective for the company. UBS Group upped their target price on Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, Barclays upped their target price on Elanco Animal Health from $30.00 to $32.00 and gave the stock an “overweight” rating in a research note on Thursday. Nine investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $30.36.

Check Out Our Latest Stock Report on ELAN

About Elanco Animal Health

(Free Report)

Elanco Animal Health is a global animal health company that develops, manufactures and markets products for companion animals and livestock. Its offerings include medicines, vaccines and other products intended to prevent and treat disease and support animal health. For pets, Elanco provides treatments for conditions including parasitic infections, pain and chronic diseases. Its livestock products support the health of animals such as cattle, poultry, swine and fish, serving producers and veterinarians.

Recommended Stories

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN – Free Report).

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.